The first large (and ambitious) randomized trial of photon versus proton post-mastectomy radiation RADCOMP is reporting its first early outcomes which include no difference on most 6-month quality of life measures with the exception of those receiving proton therapy being more likely to recommend treatment to friends. The heavy hitters of disease control and cardiac toxicity are a long time coming. | MacDonald, ASTRO 2025
